Physician profile
Robert A James
NPI 1891755716
$256.54
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.49 · 2020: $44.32 · 2021: $66.37 · 2022: $53.36.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $43.85 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $43.14 | 2019 | |
| Pfizer INC. | $36.92 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.61 | 2020 | |
| Sanofi Pasteur INC. | $28.98 | 2019-2021 | |
| Boston Scientific Corporation | $21.09 | 2021 | |
| Jazz Pharmaceuticals INC. | $18.78 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.16 | 2019 | |
| Merck Sharp & Dohme LLC | $16.01 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.